Imacent Tablet 400 mg contains Imatinib Mesylate, a targeted anticancer agent belonging to the class of protein tyrosine kinase inhibitors. It is primarily used in the management of specific malignancies driven by abnormal tyrosine kinase activity. Imatinib marked a major advancement in cancer therapy by selectively inhibiting cancer cell growth while minimizing damage to normal cells.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Antineoplastic Agent – Tyrosine Kinase Inhibitor

Indications

Imacent Tablet 400 mg is indicated for the treatment of the following conditions:

• Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast crisis

• Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)

• Gastrointestinal stromal tumors (GIST) that are unresectable, metastatic, or recurrent

• Myelodysplastic/myeloproliferative diseases are associated with specific genetic abnormalities

• Hypereosinophilic syndrome and chronic eosinophilic leukemia

• Dermatofibrosarcoma protuberans (DFSP)

Pharmacology / Mode of Action

Imatinib Mesylate selectively inhibits several tyrosine kinases, including BCR-ABL, c-KIT, and platelet-derived growth factor receptor (PDGFR). In chronic myeloid leukemia, Imatinib blocks the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome, thereby preventing proliferation of malignant cells and inducing apoptosis. In gastrointestinal stromal tumors, it inhibits c-KIT signaling, which is essential for tumor growth and survival. This targeted mechanism allows effective disease control with improved tolerability compared to conventional chemotherapy.

Dosage and Administration

Dosage should be individualized based on disease type, stage, and patient response.

• CML (chronic phase): 400 mg once daily

• CML (accelerated phase or blast crisis): Up to 600–800 mg daily as directed by a physician

• GIST: 400 mg once daily; may be increased based on clinical response

Imacent Tablet should be taken orally with a meal and a full glass of water to reduce gastrointestinal irritation. Tablets should not be crushed or chewed unless advised by a healthcare professional.

Contraindications

Imacent Tablet 400 mg is contraindicated in patients with known hypersensitivity to Imatinib Mesylate or any of the excipients.

Side Effects

Common side effects include nausea, vomiting, diarrhea, abdominal pain, edema, muscle cramps, fatigue, headache, rash, and weight gain. Hematological effects such as anemia, neutropenia, and thrombocytopenia may occur and require regular monitoring. Most adverse effects are mild to moderate and manageable with supportive care or dose adjustment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Imatinib is metabolized primarily by CYP3A4. Concomitant use with strong CYP3A4 inhibitors or inducers may alter Imatinib plasma concentrations. Caution is advised when used with warfarin, paracetamol, and certain antifungal or anticonvulsant medications.

Pregnancy and Lactation

Imacent Tablet should be avoided during pregnancy due to the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment. Breastfeeding is not recommended, as Imatinib may be excreted in breast milk.

Precautions and Warnings

Regular monitoring of liver function, complete blood counts, and renal function is recommended during therapy. Use with caution in patients with hepatic or renal impairment, cardiac disease, or fluid retention.

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.